您的位置: 首页 > 农业专利 > 详情页

BLINATUMOMAB AND ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES (BLINCYTO)
专利权人:
AMGEN RES MUNICH GMBH
发明人:
申请号:
LU93067
公开号:
LU93067I2
申请日:
2016.05.11
申请国别(地区):
LU
年份:
2016
代理人:
摘要:
The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding sites specifically binds the human CD3 antigen. The polypeptide may exist in both monomeric form and multimeric form. The multimeric form of the polypeptide constitutes no more than 5% of the total weight of the combined monomeric and multimeric forms of said polypeptide.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充